Answers are grounded in this paper and cite their sources.
Large-scale genomic analysis identifies novel vaccine targets for Aeromonas species, indicating new strategies for combating resistance.
Aeromonas species are globally significant pathogens. However, the mechanisms driving their antimicrobial resistance patterns remain unclear. This study addresses the spread of resistance genes in the Aeromonas genus through a large-scale genomic analysis of all complete Aeromonas genomes in the RefSeq database. The emergence of next-generation genomic sequencing enabled the sequencing, assembling and annotation of numerous genomes with a description and characterization of the genomic plasticity and the pan-resistome, through bioinformatics programmes, of each species in the Aeromonas genus, and revealed species-specific patterns of resistance determinants. Leveraging these genomic insights, we applied a reverse vaccinology approach with a subtractive genomic workflow to select novel in silico vaccine targets for the three main pathogens: A. veronii, A. hydrophila and A. caviae. These protein candidates offer a potential alternative to prevent the spread of antibiotic resistance genes. Our findings underscore that continuous genomic surveillance is essential for monitoring established and emerging pathogens. While further in vitro and in vivo validation is pending, this work provides a robust framework for understanding Aeromonas resistance and developing new strategies to protect public and environmental health.
No takes yet. Share an insight, caveat, or question.
Tristão et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: